Fibrocor Therapeutics is developing potential first-in-class therapies for kidney disease, with a primary focus on kidney allograft fibrosis (KAF), the scarring that can compromise the function and longevity of a transplanted kidney. Its lead program, FIB992, is being developed to target fibroblast activation and excessive collagen deposition, with the goal of preserving kidney function, extending transplant longevity and reducing the need for a return to dialysis or another transplant.

The company’s approach combines targets identified in human kidney biopsies with a clinical development strategy guided by biomarkers. Alport syndrome and chronic kidney disease (CKD) are secondary indications, reflecting the potential to apply this approach across kidney diseases in which fibrosis contributes to progressive loss of function.

Led by CEO William Newsome, alongside scientific leader Piet Wigerinck and clinical expert Paul Ford, Fibrocor brings together extensive experience in fibrosis biology, drug development and clinical strategy to advance therapies aimed at improving long-term outcomes for patients.